Skip to content
OpenCapital
Get started

Dogwood Therapeutics DWTX Interest Income (Expense), Nonoperating

Interest Income (Expense), Nonoperating at other companies

Bioventus logo
BioventusBVS
——

Other financials

Income statement

See full
Operating income-$5.1M-14.6%
Net income-$5.0M+54.4%
EPS (diluted)-$0.15+98.2%

Balance sheet

See full
Cash & equivalents$13.2M-24.6%
Total debt$144.9K-24.2%
Total equity$80.6M+1,038%
Total assets$95.2M-1.8%

Cash flow

See full
Operating cash flow-$4.6M+2.0%

Valuation

See full
Market cap$54.14M-57.6%
Enterprise value$41.06M-64.7%

Returns & leverage

See full
Return on equity-64.6%-29.8pp
Debt / equity0×0.0×
Current ratio5.9×-1.6×

Where this comes from

Reported directly by Dogwood Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:InterestIncomeExpenseNonoperatingNet.

The official record: Dogwood Therapeutics’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Dogwood Therapeutics's interest income (expense), nonoperating.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Dogwood Therapeutics's interest income (expense), nonoperating?
Dogwood Therapeutics (DWTX) reported interest income (expense), nonoperating of $77.35K in Q1 2026.
How has Dogwood Therapeutics's interest income (expense), nonoperating changed year-over-year?
Dogwood Therapeutics's interest income (expense), nonoperating increased by 152.6% year-over-year, from -$147.09K to $77.35K.
What is the long-term trend for Dogwood Therapeutics's interest income (expense), nonoperating?
Over 2 years (2023 to 2025), Dogwood Therapeutics's interest income (expense), nonoperating has grown at a -19.9% compound annual growth rate (CAGR), from $150.9K to $96.94K.